Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure

Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure

Malignant liver tumors affecting children and adolescents are rare. In order to adequately study liver tumors occurring in this patient population and establish a more uniform approach to therapy, the three primary liver tumor consortia, SIOPEL (mainly European), COG (mainly North American) and JCCG...

Full description

Saved in:
Bibliographic Details
Main Authors: Irene Schmid, Allison F. O’Neill, Kenichiro Watanabe, Isabelle Aerts, Sophie Branchereau, Penelope R. Brock, Madhumita Dandapani, Brice Fresneau, Jim Geller, Tomoro Hishiki, Danielle Ingham, Kathelijne Kraal, Milind Ronghe, Greg Tiao, Angela Trobaugh-Lotrario, Arun Rangaswami, Michael J. Sullivan, Jozsef Zsiros, Eiso Hiyama, Marcio Malogolowkin, Marc Ansari
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:EJC Paediatric Oncology
Subjects:
Hepatoblastoma
Hepatocellular Carcinoma
Hepatocellular Neoplasm – Not Otherwise Specified
Interim guidance
Children
Chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2772610X25000236
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant liver tumors affecting children and adolescents are rare. In order to adequately study liver tumors occurring in this patient population and establish a more uniform approach to therapy, the three primary liver tumor consortia, SIOPEL (mainly European), COG (mainly North American) and JCCG (Japan), in concert, designed an international prospective clinical trial [PHITT (Paediatric Hepatic International Tumour Trial)/COGAHEP1531/JPLT4 – to be referred to as PHITT from this point forth] for the study of hepatoblastoma and hepatocellular carcinoma in children and adolescents. Recruitment to PHITT has recently concluded. The major results from this trial will be published in the next 2–3 years, therefore in the interim, we sought to provide a consensus statement on evidence-based chemotherapy guidance for hepatoblastoma and hepatocellular carcinoma of all stages.
ISSN:2772-610X

Similar Items